Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized children with or without concomitant piperacillin-tazobactam

Fudan University Journal of Medical Sciences

Volumn 42, Issue 6, 2015, Pages 743-748

  Gao, Xuan ^a   Li, Jing ^a   Li, Zhi Ping ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Acute kidney injury; Child; Nephrotoxicity; Piperacillin tazobactam; Vancomycin

Indexed keywords

EID: 84949939569     PISSN: 16728467     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1672-8467.2015.06.009     Document Type: Article

References (28)

1. Kangari G, Esteghamati M, Ghasemi K, et al. Predictive accuracy of urinary beta2-microglobulin for kidney injury in children with acute pyelonephritis[J]. Iran J Kidney Dis, 2015, 9(1): 19-24.
2. Olowu WA. Acute kidney injury in children in Nigeria[J]. Clin Nephrol, 2015, 83(7 Suppl 1): 70-74.
3. Bucholz EM, Whitlock RP, Zappitelli M, et al. Cardiac biomarkers and acute kidney injury after cardiac surgery[J]. Pediatrics, 2015, 135(4): e945-956.
4. Ringenberg T, Robinson C, Meyers R, et al. Achievement of therapeutic vancomycin trough serum concentrations with empiric dosing in Neonatal Intensive Care Unit patients[J]. Pediatr Infect Dis J, 2015, 34(7): 742-747.
5. Ragab AR, Al-Mazroua MK, Al-Harony MA. Incidence and predisposing factors of vancomycin-induced nephrotoxicity in children[J]. Infect Dis Ther, 2013, 2(1): 37-46.
6. Gomez DS, Campos EV, de Azevedo RP, et al. Individualised vancomycin doses for paediatric burn patients to achieve PK/PD targets[J]. Burns, 2013, 39(3): 445-450.
7. Elyasi S, Khalili H, Dashti-Khavidaki S, et al. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review[J]. Eur J Clin Pharmacol, 2012, 68(9): 1243-1255.
8. Chen DW, Hsu YH, Liao JY, et al. Sustainable release of vancomycin, gentamicin and lidocaine from novel electrospun sandwich-structured PLGA/collagen nanofibrous membranes[J]. Int J Pharm, 2012, 430(1-2): 335-341.
9. Stidham T, Reiter PD, Ford DM, et al. Successful utilization of high-flux hemodialysis for treatment of vancomycin toxicity in a child[J]. Case Rep Pediatr, 2011, 2011: 678724.
10. Zheng H, Truong J, Carroll F, et al. Do formulation differences between the reference listed drug and generic Piperacillin-Tazobactam impact reconstitution?[J]. Antimicrob Agents Chemother, 2015, 59(3): 1767-1769.
11. Yang H, Zhang C, Zhou Q, et al. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis[J]. PLoS One, 2015, 10(1): e0116769.
12. Gomes DM, Smotherman C, Birch A, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime[J]. Pharmacotherapy, 2014, 34(7): 662-669.
13. Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam[J]. Pharmacotherapy, 2014, 34(7): 670-676.
14. Meaney CJ, Hynicka LM, Tsoukleris MG. Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors[J]. Pharma-cotherapy, 2014, 34(7): 653-661.
15. Moenster RP, Linneman TW, Finnegan PM, et al. Acute renal failure associated with vancomycin and beta-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime[J]. Clin Microbiol Infect, 2014, 20(6): O384-389.
16. Dilworth TJ, Sliwinski J, Ryan K, et al. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphy-lococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro[J]. Antimicrob Agents Chemother, 2014, 58(2): 1028-1033.
17. Dilworth TJ, Leonard SN, Vilay AM, et al. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model[J]. Clin Ther, 2014, 36(10): 1334-1344.
18. Shenoy ES, Paras ML, Noubary F, et al. Natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE): a systematic review[J]. BMC Infect Dis, 2014, 14: 177.
19. Fullmer A, McCue D, Feng C. Retrospective review of vancomycin-induced nephrotoxicity in patients with leukemia[J]. J Oncol Pharm Pract, 2014, 20(6): 403-408.
20. Ng K, Mabasa VH, Chow I, et al. Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults[J]. Neurocrit Care, 2014, 20(1): 158-171.
21. Drouet M, Chai F, Barthelemy C, et al. Influence of vancomycin infusion Methods: on endothelial cell toxicity[J]. Antimicrob Agents Chemother, 2015, 59(2): 930-934.
22. McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions[J]. Nature, 2015, 519(7542): 237-241.
23. Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. A review[J]. Med Toxicol Adverse Drug Exp, 1988, 3(5): 376-386.
24. Mergenhagen KA, Borton AR. Vancomycin nephrotoxicity: a review[J]. J Pharm Pract, 2014, 27(6): 545-553.
25. Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter[J]. Antimicrob Agents Chemother, 2013, 57(2): 734-744.
26. Elyasi S, Khalili H, Hatamkhani S, et al. Prevention of vancomycin induced nephrotoxicity: a review of preclinical data[J]. Eur J Clin Pharmacol, 2013, 69(4): 747-754.
27. Cies JJ, Jain J, Kuti JL. Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia[J]. Pediatr Blood Cancer, 2015, 62(3): 477-482.
28. Lemieux P, Gregoire JP, Thibeault R, et al. Higher risk of neutropenia associated with piperacillin-tazobactam compared with ticarcillin-clavulanate in children[J]. Clin Infect Dis, 2015, 60(2): 203-207.